Condition: Human Papillomavirus Type 16 · Cervical Intraepithelial Neoplasia Grade II · Cervical Intraepithelial Neoplasia, Grade III · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
This description comes directly from the study's public registry record.
Kimberly Levinson, MD · 4109558240 · klevins1@jhmi.edu
Ashish Solanki, RN · 410-614-6702 · asolank2@jhmi.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04131413